CorMedix Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	181.01	163.06	-17.93	-46.34	-29.7	-28.21
Depreciation & Amortization	25.33	15.39	0.46	0.21	0.21	0.18
Stock-Based Compensation	14.91	13.83	6.13	5.49	4.07	5.04
Other Adjustments	57.1	-24.49	0.14	-	-	-
Change in Receivables	-71.51	-90.92	-51.79	-	0.04	-0.04
Changes in Inventories	-4.61	-3.48	-5.49	-2.11	0	0.15
Changes in Accounts Payable	8.06	3.33	-2.56	2.08	-0.01	1.08
Changes in Accrued Expenses	53.27	100.77	22.99	3	0.96	0.09
Changes in Other Operating Activities	-2.54	-2.43	-2.55	-0.74	0.07	0.56
Operating Cash Flow	197.69	175.05	-50.62	-38.41	-24.36	-21.16
Capital Expenditures	-2.98	-2.26	-0.12	-0.33	-0.22	-1.43
Purchases of Investments	-37.97	-52.95	-26.77	-77.08	-31.14	-15.29
Proceeds from Sale of Investments	49.19	55.29	48.12	60.35	27.65	7.58
Payments for Business Acquisitions	1.49	-308.51	-	-	-	-
Investing Cash Flow	-305.27	-308.43	21.23	-17.06	-3.71	-9.13
Long-Term Debt Issued	-	150	-	-	-	-
Net Long-Term Debt Issued (Repaid)	-	150	-	-	-	-
Issuance of Common Stock	49.43	96.55	26.61	56.12	17.9	41.76
Repurchase of Common Stock	-13.59	-1.99	-0.29	-0.2	-	-
Net Common Stock Issued (Repurchased)	35.84	94.56	26.32	55.92	17.9	41.76
Other Financing Activities	-6.24	-6.11	-	-	-	-
Financing Cash Flow	220.26	238.45	26.32	55.92	17.9	41.76
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0	-0	-	0	-0.01	-0.01
Net Cash Flow	112.68	105.07	-3.07	0.45	-10.18	11.45
Free Cash Flow	194.71	172.79	-50.73	-38.74	-24.58	-22.58
Free Cash Flow Growth	12.69%	-	-	-	-	-
FCF Margin	54.04%	55.43%	-116.70%	-	-37573.50%	-11826.20%
Free Cash Flow Per Share	2.26	2.15	-0.86	-0.76	-0.61	-0.60
Levered Free Cash Flow	257.55	424.37	-5.21	-44.23	-28.69	-27.58
Unlevered Free Cash Flow	274.4	248.41	-11.25	-46.85	-29.02	-27.56

SEC Filings: 10-K · 10-Q